A method to determine the incorporation capacity of camptothecin in liposomes

AAPS PharmSciTech

Volumn 5, Issue 3, 2004, Pages

  Sætern, Ann Mari ^a   Flaten, Gøril Eide ^a   Brandl, Martin ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Camptothecin; DOTAP; Drug carriers; Incorporation; Liposomes

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CAMPTOTHECIN; CHOLESTEROL; DILAUROYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; LIPOSOME; PHOSPHATE; PHOSPHATIDYLCHOLINE;

ACIDITY; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; FREEZE DRYING; HYDROPHOBICITY; PARTICLE SIZE; PRECIPITATION; REPRODUCIBILITY; SUPERNATANT; ULTRACENTRIFUGATION; ULTRASOUND;

EID: 23144434579     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt050340     Document Type: Article

References (34)

1. Jain A, Sanghvi T, Yalkowsky SH. Liposome formulation of NSC-639829 using halothane as a solvent: a technical note. AAPS PharmSciTech. 2003;4:E52.
2. Lee K-E, Kim J-J, Yuk H-G, Jang J-Y, Lee S-C. Effect of phase transition temperature of phospholipids on the stability of retinol incorporated into liposomes. J Food Sci. 2003;8:235-238.
3. Engel A, Chatterjee SK, Al-Arifi A, Nuhn P. Influence of spacer length on the agglutination of glycolipid-incorporated liposomes by ConA as model membrane. J Pharm Sci. 2003;92:2229-2235.
4. Qi XR, Liu MH, Liu HY, Maitani Y, Nagai T. Topical econazole delivery using liposomal gel. STP Pharm Sci. 2003;13:241-245.
5. Rodriguez ME, Awruch J, Dicelio L. Photophysical properties of Zn(II) incorporated into liposomes. J Porphyr Pathalocyanin. 2002;6:122-129.
6. Socaciu C, Bojarski P, Aberle L, Diehl HA. Different ways to insert carotenoids into liposomes affect structure and dynamics of the bilayer differently. Biophys Chem. 2002;99:1-15.
7. Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Des. 2002;8:441-454.
8. Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S, et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release. 2001;74(1-3):325-333.
9. Lundberg BB. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions. Anticancer Drug Des. 1998;13:453-461.
10. Sugarman SM, Zou YY, Wasan K, et al. Lipid complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol. 1996;37:531-538.
11. Cortesi R, Esposito E, Maietti A, Menegatti E, Nastruzzi C. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int J Pharm. 1997;159:95-103.
12. Burke TG, Mishra AK, Wani MC, Wall ME. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry. 1993;32:5352-5364.
13. Daoud SS, Fetouh MI, Giovanella BC. Antitumor effect of liposome-incorporated camptothecin in human-malignant xenografts. Anticancer Drugs. 1995;6:83-93.
14. Chow DS, Gong L, Wolfe MD, Giovanella BC. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin. Ann N Y Acad Sci. 2000;922:164-174.
15. Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R, et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release. 2003;91(1-2):167-172.
16. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722-1726.
17. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077-5082.
18. Mattern MR, Mong SM, Bartus HF, Mirabelli CK, Crooke ST, Johnson RK. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase-I in cultured L1210 cells. Cancer Res. 1987;47:1793-1798.
19. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M. Complete growth-inhibition of human cancer xenografts in nude-mice by treatment with 20-(S)-camptothecin. Cancer Res. 1991;51:3052-3055.
20. Pantazis P, Hinz HR, Mendoza JT, et al. Complete inhibition of growth followed by death of human-malignant melanoma-cells in vitro and regression of human-melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 1992;52:3980-3987.
21. Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC. Growth-inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res. 1995;55:5637-5641.
22. Scott DO, Bindra DS, Stella VJ. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res. 1993;10:1451-1457.
23. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase-I and biological-activity. J Med Chem. 1989;32:715-720.
24. Gabizon A. Emerging role of liposomal drug carrier systems in cancer chemotherapy. J Liposome Res. 2003;13:17-20.
25. Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat. 2000;3:171-177.
26. Beckman®. Instructions for using the SW60 titanium rotor in class G H preparative ultracentrifuges. Spingo division of Backman Instruments, Inc. Palo Alto, California: 1978; LE-TB-002D.
27. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Sci Appl. 1997;691(1):161-171.
28. Grohganz H, Ziroli V, Massing U, Brandl M. Quantification of various phosphatidylcholines in liposomes by enzymatic assay. AAPS PharmSciTech. 2003;4:E63.
29. Wako. Phospholipid B, enzymatic colorimetric method for the quantitative determination of phospholipids in serum and plasma. Code nr. 990-54009 E, Wako Chemicals GmbH: Neuss, Germany.
30. Frantzen C, Ingebrigtsen L, Skar M, Brandl M. Assessing the accuracy of routine photon correlation spectroscopy analysis of heterogeneous size distributions. AAPS PharmSciTech. 2003;4:E36.
31. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004;270(1-2):93-107.
32. Zhang JA, Pawelchak J. Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC/cholesterol liposomes under accelerated conditions. Part 1: Lipid hydrolysis. Eur J Pharm Biopharm.. 2000;50:357-364.
33. Grit M, Desmidt JH, Struijke A, Crommelin DJA. Hydrolysis of phosphatidylcholine in aqueous liposome dispersions. Int J Pharm. 1989;50:1-6.
34. Perez-Soler R, Sugarman SM, Poirot KR, inventors. Lipid complexed topoisomerase I inhibitors. US patent 5 834 012. November 10, 1998.